Paul M. Matthews, M.D.
Paul M. Matthews, M.D., is vice president for imaging, genetics, and neurology in clinical pharmacology and discovery medicine at GlaxoSmithKline (GSK) and head of the GSK Clinical Imaging Centre,Hammersmith Hospital, London. He is also professor of clinical neurosciences at Imperial College, London, and (honorary) MRC clinical research professor at the University of Oxford. He is the co author, with Jeffrey McQuain, of The Bard on the Brain: Understanding the Mind Through the Art of Shakespeare and the Science of Brain Imaging (Dana Press 2003), author of more than 100 scientific articles, and author or contributor to more than 50 books. He received a Ph.D. in biochemistry from Oxford and an M.D. from Stanford University School of Medicine. He can be contacted at firstname.lastname@example.org.
The Long, Sometimes Bumpy Road of Drug Development
The current arduous process of drug development may be improved through brain imaging.
Transforming Drug Development Through Brain Imaging
After years of research and enormous expense, perhaps only one in a hundred potential drugs for a brain disorder will receive government approval and make it to the person who needs it. Neuroimaging may change this dramatically.